MANNKIND CORP Business Acquisition, Pro Forma Net Income (Loss)
MANNKIND CORP (MNKD) reported Business Acquisition, Pro Forma Net Income (Loss) of -$5.26 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-08-07
- MANNKIND CORP business acquisition, pro forma net income (loss) for the quarter ending 2023-06-30 was -$5.26M.
- MANNKIND CORP business acquisition, pro forma net income (loss) for the quarter ending 2023-03-31 was -$9.79M.
- MANNKIND CORP business acquisition, pro forma net income (loss) for the quarter ending 2022-12-31 was -$17.95M.
- MANNKIND CORP business acquisition, pro forma net income (loss) for the quarter ending 2022-09-30 was -$14.12M.
- MANNKIND CORP business acquisition, pro forma net income (loss) for fiscal 2022 was -$86.97M.
- MANNKIND CORP business acquisition, pro forma net income (loss) for fiscal 2021 was -$80.81M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$5.26M 10-Q · filed 2023-08-07 | -$15.06M 10-Q · filed 2023-08-07 | -$33.01M derived: sum of 3 quarters · filed 2023-08-07 | -$47.13M derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | -$9.79M 10-Q · filed 2023-05-09 | -$27.74M derived: sum of 2 quarters · filed 2023-05-09 | -$41.87M derived: sum of 3 quarters · filed 2023-05-09 | -$70.63M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-12-31 | -$17.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$32.07M derived: sum of 2 quarters · filed 2023-02-23 | -$60.83M derived: sum of 3 quarters · filed 2023-08-07 | -$86.97M 10-K · filed 2023-02-23 |
| 2022-09-30 | -$14.12M 10-Q · filed 2022-11-08 | -$42.89M derived: sum of 2 quarters · filed 2023-08-07 | -$69.02M 10-Q · filed 2022-11-08 | -$96.43M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-06-30 | -$28.76M 10-Q · filed 2023-08-07 | -$54.51M 10-Q · filed 2023-08-07 | -$82.31M derived: sum of 3 quarters · filed 2023-08-07 | -$86.57M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$25.74M 10-Q · filed 2023-05-09 | -$53.54M derived: sum of 2 quarters · filed 2023-05-09 | -$57.81M derived: sum of 3 quarters · filed 2023-05-09 | -$93.35M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$27.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$32.06M derived: sum of 2 quarters · filed 2023-02-23 | -$67.61M derived: sum of 3 quarters · filed 2023-02-23 | -$80.81M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$4.26M 10-Q · filed 2022-11-08 | -$39.81M derived: sum of 2 quarters · filed 2022-11-08 | -$53.01M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$35.55M 10-Q · filed 2022-08-09 | -$48.78M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |